Foghorn Therapeutics is a developer of gene therapies for hematologic cancers and solid tumors. Through its Gene Traffic Control platform, the company studies, identifies, and validates potential drug targets within the chromatin regulatory system.
Net income (H1, 2020)
EBIT (H1, 2020)
Market capitalization (20-Nov-2020)
Closing stock price (20-Nov-2020)
|Company Name||Date||Deal Size|
|Foghorn Securities Corporation|
Foghorn Therapeutics has 503 Twitter Followers. The number of followers has increased 11.7% month over month and increased 16.8% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was Foghorn Therapeutics founded?
Foghorn Therapeutics was founded in 2016.
Who are Foghorn Therapeutics key executives?
Foghorn Therapeutics's key executives are Adrian Gottschalk, Samuel Agresta and Fanny Cavalié.
How many employees does Foghorn Therapeutics have?
Foghorn Therapeutics has 85 employees.
Who are Foghorn Therapeutics competitors?
Competitors of Foghorn Therapeutics include Nurix, Kymera Therapeutics and Arvinas.
Where is Foghorn Therapeutics headquarters?
Foghorn Therapeutics headquarters is located at NE47, 500 Technology Square #700, Cambridge.
Where are Foghorn Therapeutics offices?
Foghorn Therapeutics has an office in Cambridge.
How many offices does Foghorn Therapeutics have?
Foghorn Therapeutics has 1 office.
Receive alerts for 300+ data fields across thousands of companies